Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222

mRNA-1273.222 Targets BA.4/BA.5 Strains of Omicron Variant Pending Authorization, Moderna Ready to Ship Bivalent Booster mRNA-1273.222 in September Clinical Data Available for Moderna ' s Bivalent COVID-19 Booster Vaccines Have Met All Primary...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials